Las Vegas, NV – April 08, 2014 — (TechSonian) – Genco Shipping & Trading, (NYSE:GNK), engages in the ocean transportation of drybulk cargoes through the ownership and operation of drybulk carrier vessels worldwide. It transports iron ore, coal, grain, steel products, and other drybulk cargoes.
Genco Shipping & Trading Limited (NYSE:GNK) opened the session at $1.67, trading in a range of $1.52 – $1.90, and closed at $1.79. The stock showed a negative performance of -7.73% in the last trading session. The stock traded on a volume of 5.59 million shares and the average volume of the stock remained 3.60 million shares.
Will GNK Get Buyers Even After The Recent Rally? Find Out Here
EnteroMedics, (NASDAQ:ETRM), posted that the U.S. Food and Drug Administration’s Office of Device Evaluation has reorganized a meeting of the Center for Devices and Radiologic Health’s (CDRH) Advisory Committee for Tuesday, June 17, 2014 to review the Maestro System delivering VBLOC vagal blocking therapy as a treatment for morbid obesity.
EnteroMedics Inc (NASDAQ:ETRM) traded 1.51 million shares in the last business day while the average volume of the stock remained 1.18 million shares. The stock showed a negative movement of -7.78% to end at $1.66. The 52 week range of the stock remained $0.81 – $2.66. Has ETRM Found The Bottom And Ready To Gain Momentum? Find Out Here
ANADIGICS, (NASDAQ:ANAD), updated that the Company’s AWL9293 and AWL9581 802.11ac front-end integrated circuits (FEICs) are enabling WiFi connectivity in the new GALAXY Tab Pro by Samsung Electronics. This feature-rich tablet includes a 10.1-inch WQXGA resolution display, Exynos(R) 5 Octa processor, 8 megapixel camera and Android(R) 4.4 KitKat operating system.
ANADIGICS, Inc. (NASDAQ:ANAD) reported 2.52 million shares were exchanged during the last trade, while the average volume is about 623,372 shares. The stock dropped -8.23% and finished the day at $1.45. The beta of the stock is recorded at 2.08.
Why Should Investors Buy ANAD After the Recent Fall? Just Go Here and Find Out
Catalyst Pharmaceutical Partners, (NASDAQ:CPRX) a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological ailments reported its financial results for the 4th quarter and year-ended 31st December, 2013.
Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) the stock decreased -8.85% and finished the session at $2.06. Traded with volume of 1.73 million shares in the prior session and the average volume of the stock remained 1.07 million shares.
Will CPRX Get Buyers Even After The Recent Rally? Find Out Here